TABLE 1.
MICs of 13 antimicrobial agents against 142 isolates of Acinetobacter baumannii-calcoaceticus complex from deployed and nondeployed U.S. military patientsa
| Drugb | Result for:
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deployed personnel (n = 95)
|
Nondeployed personnel (n = 47)
|
|||||||||||||||
| MIC (μg/ml)c
|
% Susceptibled | MIC (μg/ml)c
|
% Susceptibled | |||||||||||||
| Range | 50% | 90% | Range | 50% | 90% | |||||||||||
| Ampicillin-sulbactam
|
||||||||||||||||
| No-growth end point | 2->128 | 32 | 128 | 16* | 2->128 | 16 | 128 | 47* | ||||||||
| Trailing end point | 2-128 | 16 | 64 | 38* | ≤1->128 | 8 | 32 | 60* | ||||||||
| Sulbactam
|
||||||||||||||||
| No-growth end point | ≤2->64 | 16 | 64 | —e | ≤2->64 | 8 | 64 | — | ||||||||
| Trailing end point | ≤2-32 | 8 | 32 | — | ≤2-32 | 4 | 32 | — | ||||||||
| Imipenem
|
||||||||||||||||
| No-growth end point | ≤0.5->16 | 2 | >16 | 63* | ≤0.5->16 | 1 | >16 | 87* | ||||||||
| Trailing end point | ≤0.5->16 | 1 | >16 | 66* | ≤0.5->16 | ≤0.5 | >16 | 87* | ||||||||
| Ticarcillin-clavulanate
|
||||||||||||||||
| No-growth end point | 8->256 | >256 | >256 | 5* | 4->256 | 64 | >256 | 26* | ||||||||
| Trailing end point | ≤2->256 | >256 | >256 | 8* | ≤2->256 | 32 | >256 | 34* | ||||||||
| Ceftazidime
|
||||||||||||||||
| No-growth end point | 8->64 | 64 | >64 | 9* | 4->64 | >64 | 64 | 34* | ||||||||
| Trailing end point | 2->64 | 32 | >64 | 33 | 2->64 | 32 | >64 | 45 | ||||||||
| Colistin | 0.25-8 | 1 | 1 | 99 | 0.5-8 | 1 | 2 | 96 | ||||||||
| Polymyxin B | 0.5-4 | 1 | 2 | 99 | 0.5-4 | 1 | 2 | 98 | ||||||||
| Amikacin | ≤0.5->64 | 16 | >64 | 50 | 1->64 | 8 | >64 | 51 | ||||||||
| Gentamicin | ≤0.5->8 | >8 | >8 | 7* | ≤0.5->8 | >8 | >8 | 38* | ||||||||
| Azithromycin | <1->8 | >8 | >8 | — | 2->8 | >8 | >8 | — | ||||||||
| Doxycycline | ≤0.25->16 | 8 | >16 | 40 | ≤0.25->16 | 4 | >16 | 62 | ||||||||
| Minocycline | ≤0.12-16 | 1 | 4 | 97 | ≤0.12-8 | 0.5 | 4 | 98 | ||||||||
| Tigecycline | 0.12->8 | 2 | 8 | — | 0.12->8 | 1 | 2 | — | ||||||||
Deployed personnel are those who received care after suffering an injury while deployed in support of OIF or OEF (the current war in Afghanistan). Nondeployed personnel are those inpatients receiving care without a history of deployment in support of OIF/OEF.
No-growth end point, MIC defined as the concentration that inhibited all visible bacterial growth; trailing end point, MIC defined as the concentration at which growth was reduced ≥80%. With a trailing end point, colonies or subtle growth patterns occurred above the determined MIC.
50 and 90%, MICs at which 50 and 90% of isolates are inhibited, respectively.
According to CLSI criteria, except where otherwise indicated. *, P ≤ 0.01 for difference between isolates from deployed and nondeployed personnel.
—, no interpretive criteria available.